Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year 2024 and Recent Corporate Highlights Regulatory New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review in August 2024. The FDA extended the review period and assigned an updated Prescription Drug User Fee Act (PDUFA) target action date of March 27, 2025.Granted Breakthrough Therapy Designation by the FDA for DCCR for the treatment of adults and children ages four years and older with genetically confirmed PWS who have hyperphagia in April 2024. Commercial Readiness Continued strengthening
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred LossesPR Newswire
- Soleno Therapeutics (SLNO) Valuation Check After Wolfe Research's Optimistic New Coverage and Stock Pop [Yahoo! Finance]Yahoo! Finance
- How Soleno Therapeutics' Audit Committee Leadership Transition At Soleno Therapeutics (SLNO) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNOPR Newswire
- Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? [Yahoo! Finance]Yahoo! Finance
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- SLNO's page on the SEC website